Acronym | TransPharm
|
Grant Agreement ID | 101057816
|
Implementation period | 01.06.2022. – 31.05.2026. |
Coordinator | Universiteit Gent (Belgium) |
Programmes | HORIZON.2.1 – Health (main), |
HORIZON.2.1.5 – Tools, Technologies and Digital Solutions for Health and Care, including personalised medicine | |
Call for proposal | HORIZON-HLTH-2021-IND-07 |
Total Budget | € 8 077 101,25 (EU contribution
€ 8 039 600,25) |
Project participants (10) | University of Helsinki, Finland |
Circa Group AS, Norway | |
Radboud University Nijmegen, Netherlands | |
Leuphana University, Germany | |
KelAda Pharmachem, Ireland | |
Orion Corporation, Finland | |
National Institute for Public Health and the Environment, Netherlands | |
Ecologic Institute GmbH, Germany | |
Benkei, France | |
Latvian Institute of Organic Synthesis (LIOS),
Latvia | |
Partner | University of York, United Kingdom |
LIOS Budget | € 425 060,00 (EU contribution) |
Project leader in LIOS | Prof. Aigars Jirgensons |
Anna Lielpētere, PhD |
Pharmaceuticals comprise a wide variety of chemical compounds designed to guarantee safe and effective therapies. The active pharmaceutical ingredients (APIs) are those that deliver the beneficial health effects experienced by patients. The goal of the EU-funded TransPharm project is to develop more sustainable and greener APIs that simultaneously reduce the environmental footprint and the dependence on third countries for API production. TransPharm will deliver digital tools and guidelines based on artificial intelligence for the development of greener pharmaceutical products and APIs, as well as models to judge their impact. The result will be a more independent and competitive European pharmaceutical industry, which can ensure the timely delivery of sustainable and green therapeutics to its citizens.